Drug Trial News

RSS

Phase 3 trial shows acoramidis safe and effective for transthyretin amyloid cardiomyopathy

Pumping over 100,000 times a day, the heart is a critical muscle needed to deliver oxygen and nutrients to our organs to sustain healthy bodily function.

16 Jan 2024

Vanderbilt launches $13 million trial to test repurposed drugs for Rett syndrome

Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome.

16 Jan 2024

Groundbreaking drug offers new hope for life-threatening heart condition

People diagnosed with a life-threatening cardiac condition have been given new hope, thanks to a ground-breaking new drug that protects the heart developed by researchers from UCL and the Royal Free Hospital.

11 Jan 2024

University of Oxford launches first-in-human trial of the ChAdOx1 NipahB vaccine

The University of Oxford has launched a new clinical trial to test a vaccine to protect people against deadly Nipah virus.

11 Jan 2024

Extended liver preservation technique shows promise for daytime transplants

Phase II clinical trial evaluates the safety and feasibility of prolonged DHOPE for extending human donor liver preservation to 20 hours, showing potential for facilitating daytime liver transplantation.

11 Jan 2024

Carvedilol improves heart health marker in childhood cancer survivors

Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the Children's Oncology Group (COG), have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.

9 Jan 2024

Children with neuroblastomas may benefit from new drug cocktail

Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumor drugs as well as chemotherapy, a new trial has found.

9 Jan 2024

Breakthrough drug halts lung cancer and brain metastases

D'Or Institute for Research and Education (IDOR) played an important role in the phase III LIBRETTO-431 multicenter study, which evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pembrolizumab (immune checkpoint inhibitor) in non-small cell lung cancer (NSCLC).

5 Jan 2024

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

Study demonstrates that combining dapagliflozin and semaglutide significantly improves glycemic control and other health parameters in type 2 diabetes patients, outperforming dapagliflozin alone.

3 Jan 2024

Scientists design non-hallucinogenic psychedelic treatments potentially accelerating research on mental health benefits

Researchers identified 5-hydroxytryptamine 2A (5-HT2A) receptor (5-HT2AR) signaling pathways associated with psychedelic potential.

19 Dec 2023

Psilocybin may benefit individuals with cancer and major depression

Results from a phase II clinical trial indicate that psilocybin, a hallucinogenic chemical found in certain mushrooms of the genus Psiloybe, may benefit individuals with cancer and major depression.

18 Dec 2023

Experimental drug paired with a standard-care medication offers hope for kidney disease patients

In a clinical trial of patients with chronic kidney disease, an experimental drug significantly reduced albuminuria -; albumin in urine, a sign of kidney damage -; for 50% of participants.

15 Dec 2023

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer.

14 Dec 2023

Researchers find powerful combo weapon against aggressive lymphoma

The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

12 Dec 2023

Study highlights the necessity to refine the design of randomized cancer drugs trials in China

More than one-eighth of the randomized trials of cancer drugs seeking regulatory approval in China in recent years used inappropriate controls to test the effectiveness and safety of the drugs, according to a new study published December 12th in the open access journal PLOS Medicine by Professor Xiaodong Guan of Peking University, China, and colleagues.

12 Dec 2023

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study.

From SolasCure 12 Dec 2023

New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

11 Dec 2023

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a 'surprisingly high' response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.

11 Dec 2023

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year.

11 Dec 2023

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023

Drug Trial News

Phase 3 trial shows acoramidis safe and effective for transthyretin amyloid cardiomyopathy

Vanderbilt launches $13 million trial to test repurposed drugs for Rett syndrome

Groundbreaking drug offers new hope for life-threatening heart condition

University of Oxford launches first-in-human trial of the ChAdOx1 NipahB vaccine

Extended liver preservation technique shows promise for daytime transplants

Carvedilol improves heart health marker in childhood cancer survivors

Children with neuroblastomas may benefit from new drug cocktail

Breakthrough drug halts lung cancer and brain metastases

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

Scientists design non-hallucinogenic psychedelic treatments potentially accelerating research on mental health benefits

Psilocybin may benefit individuals with cancer and major depression

Experimental drug paired with a standard-care medication offers hope for kidney disease patients

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Researchers find powerful combo weapon against aggressive lymphoma

Study highlights the necessity to refine the design of randomized cancer drugs trials in China

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

New combination treatment offers hope for older patients with mantle cell lymphoma

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News